-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellgram-LC in Decompensated Cirrhosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellgram-LC in Decompensated Cirrhosis Drug Details: Livercellgram is under development for the treatment of alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellgram-LC in Liver Cirrhosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cellgram-LC in Liver CirrhosisDrug Details:Livercellgram is under development for the treatment of alcoholic liver cirrhosis (decompensated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Immuncell-LC in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Immuncell-LC in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Immuncell-LC is an anti-cancer immune therapeutic agent, that...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology in Cervical Cancer Drug Details:Gene therapy is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology in Gastric Cancer Drug Details:Gene therapy is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology in Breast Cancer Drug Details:Gene therapy is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology in Lung Cancer Drug Details:Gene therapy is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Kk-Lc-1 For Oncology in Epithelial Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology in Epithelial TumorDrug Details:Gene therapy is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anselamimab in Primary Systemic Amyloidosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Anselamimab in Primary Systemic AmyloidosisDrug Details:Anselamimab (CAEL-101) is under development for the treatment of relapsed or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 820 TCR in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. 820 TCR in Breast Cancer Drug Details: Gene therapy is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.